GlassScriptPhysician profile
Matthew O Okeke
NPI 1730272709
$4,658.48
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $175 · 2021: $472 · 2022: $3,536 · 2023: $84.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $84.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $84.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $3,048.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $673.56 | 2019-2023 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $247.30 | 2019-2023 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.31 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.48 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $89.56 | 2019-2022 | |
| Alkermes, INC. | $88.18 | 2019-2022 | |
| Lundbeck LLC | $53.73 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $42.33 | 2019-2022 | |
| Bausch Health US, LLC | $37.27 | 2022 | |
| Neos Therapeutics, LP | $34.93 | 2019-2020 | |
| Almatica Pharma LLC | $19.49 | 2021 | |
| Eisai INC. | $14.87 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.78 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.56 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Okeke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.